Minjuvi (Tafasitamab)

• Minjuvi (tafasi­tamab) acts on CD19‑expressing B‑cell malignancies, specifically diffuse large B‑cell lymphoma.
• Relapsed or refractory diffuse large B‑cell lymphoma in adults: improves response rates when given with lenalidomide.
• Adults with DLBCL who have failed prior therapy: offers an alternative therapeutic option as part of a combination regimen.
• Combination therapy with lenalidomide: synergistic effect enhances overall treatment efficacy in DLBCL.

• Tafasitamab is a humanized IgG1 monoclonal antibody that binds with high affinity to the CD19 antigen expressed on the surface of normal and malignant B‑lymphocytes. Upon binding, the Fc region engages immune effector cells, triggering antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity, leading to selective depletion of CD19‑positive B cells. The resulting reduction in malignant B‑cell clones contributes to disease control in diffuse large B‑cell lymphoma.

Tafasitamab may be associated with a range of adverse reactions observed in clinical use.

Common Side Effects

• Fatigue: persistent tiredness that may affect daily activities.
• Nausea: sensation of needing to vomit, sometimes accompanied by loss of appetite.
• Fever: elevated body temperature, often with chills or sweating.
• Infusion‑related reactions: flushing, rash, shortness of breath, or mild hypotension during administration.

Serious or Rare Side Effects

• Severe infections: increased susceptibility to bacterial, viral, or fungal infections requiring prompt medical attention.
• Cytokine release syndrome: systemic inflammatory response that can cause hypotension, fever, and organ dysfunction.
• Tumor lysis syndrome (rare): rapid breakdown of tumor cells leading to metabolic abnormalities such as hyperuricemia and renal impairment.

Before initiating tafasitamab therapy, several safety considerations should be reviewed.

• Monitor blood counts: regular CBC testing to detect neutropenia or thrombocytopenia.
• Assess infection risk: screen for active infections and consider prophylactic measures.
• Evaluate hepatic function: check liver enzymes prior to and during treatment.
• Avoid in patients with known hypersensitivity to monoclonal antibodies: discontinue if severe allergic reaction occurs.
• Pregnancy and breastfeeding: use only if potential benefit justifies potential risk; discuss with obstetric specialist.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tafasitamab can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Concurrent use of other B‑cell depleting agents (e.g., rituximab): may cause excessive immunosuppression.
• Live vaccines: increased risk of vaccine‑derived infection; avoid administration during treatment.

Moderate Interactions (Monitor Closely)

• Lenalidomide: dose adjustments may be required to manage overlapping toxicities.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential bleeding risk.
• CYP450 substrates with narrow therapeutic index: observe plasma levels as immune modulation may alter metabolism.